Towards individualized medicine: Flies lead the way

Future Neurology

Volumn 2, Issue 4, 2007, Pages 389-396

  Elliott, Jamie L ^a   Yin, Jerry C P ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Disease modeling; Drosophila melanogaster; Drug development; Endophenotypes; Forward screens; Neurological disease

Indexed keywords

2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; AMYLOID PRECURSOR PROTEIN; FENOBAM; FRAGILE X MENTAL RETARDATION PROTEIN; GAMMA SECRETASE; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR ANTAGONIST; PRESENILIN 1; PRESENILIN 2; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BEHAVIOR THERAPY; BLOOD BRAIN BARRIER; CIRCADIAN RHYTHM; CLINICAL TRIAL; COGNITIVE DEFECT; DEVELOPMENTAL DISORDER; DISEASE MODEL; DROSOPHILA MELANOGASTER; DRUG SCREENING; ENVIRONMENTAL FACTOR; FAMILIAL DISEASE; FRAGILE X SYNDROME; GENE IDENTIFICATION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HIGH THROUGHPUT SCREENING; HUMAN; LEARNING DISORDER; MEMORY DISORDER; MOLECULAR GENETICS; MUSHROOM BODY; NEUROLOGIC DISEASE; NONHUMAN; OCCUPATIONAL THERAPY; PHENOTYPIC VARIATION; PRIORITY JOURNAL; REVIEW; SYNAPTIC TRANSMISSION; TEMPERATURE SENSITIVITY;

EID: 34447306864     PISSN: 14796708     EISSN: None     Source Type: Journal    
DOI: 10.2217/14796708.2.4.389     Document Type: Review

References (53)

1. Reiter LT, Potocki L, Chien S, Gribskov M, Bier E: A systematic analysis of human disease-associated gene sequences in Drosophila melanogaster. Genome Res. 11 (6), 1114-1125 (2001).
2. Heisenberg M: Mushroom body memoir: from maps to models. Nat. Rev. Neurosci. 4(4), 266-275 (2003).
3. Littleton JT, Ganetzky B: Ion channels and synaptic organization: analysis of the Drosophila genome. Neuron 26(1), 35-43 (2000).
4. Pesah Y, Pham T, Burgess H et al.: Drosophila parkin mutants have decreased mass and cell size and increased sensitivity to oxygen radical stress. Development 131 (9), 2183-2194 (2004).
5. Park J, Lee SB, Lee S et al.: Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 441(7097), 1157-1161 (2006).
6. Clark IE, Dodson MW, Jiang C et al.: Drosophila PINK1 is required for mitochondrial function and interacts genetically with parkin. Nature 441(7097), 1162-1166 (2006).
7. Meulener M, Whitworth AJ, Armstrong-Gold CE et al.: Drosophila DJ-1 mutants are selectively sensitive to environmental toxins associated with Parkinson's disease. Curr. Biol. 15(17), 1572-1577 (2005).
8. Satterfield TF, Jackson SM, Pallanck LJ: A Drosophila homolog of the polyglutamine disease gene SCA2 is a dosage-sensitive regulator of actin filament formation. Genetics 162(4), 1687-1702 (2002).
9. Wolfgang WJ, Miller TW, Webster JM et al.: Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies. Proc. Natl Acad. Sci. USA 102(32), 11563-11568 (2005).
10. Merdes G, Soba P, Loewer A, Bilic MV, Beyreuther K, Paro R: Interference of human and Drosophila APP and APP-like proteins with PNS development in Drosophila. EMBO J. 23(20), 4082-4095 (2004).
11. Greeve I, Kretzschmar D, Tschape JA et al.: Age-dependent neurodegeneration and Alzheimer-amyloid plaque formation in transgenic Drosophila. J. Neurosci. 24(16), 3899-3906 (2004).
12. Blard O, Feuillette S, Bou J et al.: Cytoskeleton proteins are modulators of mutant tau-induced neurodegeneration in Drosophila. Hum. Mol. Genet. 16(5), 555-566 (2007).
13. Bilen J, Bonini NM: Drosophila as a model for human neurodegenerative disease. Annu. Rev. Genet. 39, 153-171 (2005).
14. Michno K, van de Hoef D, Wu H, Boulianne GL: Demented flies? Using Drosophila to model human neurodegenerative diseases. Clin. Genet. 67(6), 468-475 (2005).
15. Zafeiriou DI, Ververi A, Vargiami E: Childhood autism and associated comorbidities. Brain Dev. 29(5), 257-272 (2006).
16. Berry-Kravis E: Epilepsy in Fragile X syndrome. Dev. Med. Child Neurol. 44(11), 724-728 (2002).
17. McBride SM, Choi CH, Wang Y et al.: Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a Drosophila model of Fragile X syndrome. Neuron 45(5), 753-764 (2005).
18. Kelley D, Davidson RJ, Yin JC, Bhattacharyya A: The cyclic AMP cascade is altered in Fragile X neural tissue. Presented at: Society for Neuroscience Annual Meeting. Atlanta, GA, USA, 14-18 October 2006 (Abstract 196.15/OO20).
19. Yan QJ, Rammal M, Tranfaglia M, Bauchwitz RP: Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology 49(7), 1053-1066 (2005).
20. Capelli LP, Goncalves MR, Kok F et al.: Fragile X-associated tremor/ataxia syndrome: intrafamilial variability and the size of the FMR1 premutation CGG repeat. Mov. Disord. 22(6), 866-870 (2007).
21. Jin P, Zarnescue DC, Zhang F et al.: RNA-mediated neurodegeneration caused by the Fragile X premutation rCGG repeats in Drosophila. Neuron 39(5), 739-747 (2003).
22. Hessl D, Tassone F, Loesch DZ et al.: Abnormal elevation of FMR1 mRNA is associated with psychological symptoms in individuals with the Fragile X premutation. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 139(1), 115-121 (2005).
23. Wittenberger MD, Hagerman RJ, Sherman SL et al.: The FMR1 premutation and reproduction. Fertil. Steril. 87(3), 456-465 (2006).
24. Costa A, Wang Y, Dockendorff TC et al.: The Drosophila Fragile X protein functions as a negative regulator in the orb autoregulatory pathway. Dev. Cell 8(3), 331-342 (2005).
25. Loat CS, Craig G, Plomin R, Craig IW: Investigating the relationship between FMR1 allele length and cognitive ability in children: a subtle effect of the normal allele range on the normal ability range? Ann. Hum. Genet. 70(Pt 5), 555-565 (2006).
26. Duering M, Grimm MO, Grimm HS, Schroder J, Hartmann T: Mean age of onset in familial Alzheimer's disease is determined by amyloid β42. Neurobiol. Aging 26(6), 785-788 (2005).
27. Mehta ND, Refolo LM, Eckman C et al.: Increased Aβ42(43) from cell lines expressing presenilin 1 mutations. Ann. Neurol. 43(2), 256-258 (1998).
28. Murayama O, Tomita T, Nihonmatsu N et al.: Enhancement of amyloid β42 secretion by 28 different presenilin 1 mutations of familial Alzheimer's disease. Neurosci. Lett. 265(1), 61-63 (1999).
29. Seidner GA, Ye Y, Faraday MM, Alvord WG, Fortini ME: Modeling clinically heterogeneous presenilin mutations with transgenic Drosophila. Curr. Biol. 16(10), 1026-1033 (2006).
30. Kumar-Singh S, Theuns J, Van Broeck B et al.: Mean age-of-onset of familial Alzheimer disease caused by presenilin mutations correlates with both increased Aβ42 and decreased Aβ40. Hum. Mutat. 27(7), 686-695 (2006).
31. Zhou S, Zhou H, Walian PJ, Jap BK: Regulation of γ-secretase activity in Alzheimer's disease. Biochemistry 46(10), 2553-2563 (2007).
32. St Johnston D: The art and design of genetic screens: Drosophila melanogaster. Nat. Rev. Genet. 3(3), 176-188 (2002).
33. Abou-Sleiman PM, Hanna MG, Wood NW: Genetic association studies of complex neurological diseases. J. Neurol. Neurosurg. Psychiatry 77(12), 1302-1304 (2006).
34. Palladino MJ, Hadley TJ, Ganetzky B: Temperature-sensitive paralytic mutants are enriched for those causing neurodegeneration in Drosophila. Genetics 161(3), 1197-1208 (2002).
35. Gnerer JP, Kreber RA, Ganetzky B: Wasted away, a Drosophila mutation in triosephosphate isomerase, causes paralysis, neurodegeneration, and early death. Proc. Natl Acad. Sci. USA 103(41), 14987-14993 (2006).
36. Min KT, Benzer S: Spongecake and eggroll: two hereditary diseases in Drosophila resemble patterns of human brain degeneration. Curr. Biol. 7(11), 885-888 (1997).
37. Tschape JA, Hammerschmied C, Muhlig-Versen M, Athenstaedt K, Daum G, Kretzschmar D: The neurodegeneration mutant lochrig interferes with cholesterol homeostasis and APPl processing. EMBO J. 21(23), 6367-6376 (2002).
38. Botella JA, Ulschmid JK, Gruenewald C et al.: The Drosophila carbonyl reductase sniffer prevents oxidative stress-induced neurodegeneration. Curr. Biol. 14(19), 782-786 (2004).
39. Hara H: Autism and epilepsy: a retrospective follow-up study. Brain Dev. doi: 10.1016/j.braindev.2006.12.012 (2007) (Epub ahead of print).
40. Svetec N, Ferveur JF: Social experience and pheromonal perception can change male-male interactions in Drosophila melanogaster. J. Exp. Biol. 208(Pt 5), 891-898 (2005).
41. Robin? C, Daborn PJ, Hoffmann AA: Fighting fly genes. Trends Genet. 23(2), 51-54 (2007).
42. Hollingworth P, Hamshere ML, Moskvina V et al.: Four components describe behavioral symptoms in 1120 individuals with late-onset Alzheimer's disease. J. Am. Geriatr. Soc. 54(9), 1348-1354 (2006).
43. Germano C, Kinsella GJ: Working memory and learning in early Alzheimer's disease. Neuropsychol. Rev. 15(1), 1-10 (2005).
44. Drier EA, Tello MK, Cowan M et al.: Memory enhancement and formation by atypical PKM activity in Drosophila melanogaster. Nat. Neurosci. 5(4), 316-324 (2002).
45. Craig D, Hart DJ, Passmore AP: Genetically increased risk of sleep disruption in Alzheimer's disease. Sleep 29(8), 1003-1007 (2006).
46. Koh K, Evans JM, Hendricks JC, Sehgal A: A Drosophila model for age-associated changes in sleep-wake cycles. Proc. Natl Acad. Sci. USA 103(37), 13843-13847 (2006).
47. Gramowski A, Jugelt K, Stuwe S et al.: Functional screening of traditional antidepressants with primary cortical neuronal networks grown on multielectrode neurochips. Eur. J. Neurosci. 24(2), 455-465 (2006).
48. Pollitt SK, Pallos J, Shau J et al.: A rapid cellular FRET assay of polyglutamine aggregation identifies a novel inhibitor. Neuron 40(4), 685-694 (2003).
49. Stilwell GE, Saraswati S, Littleton JT, Chouinard SW: Development of a Drosophila seizure model for in vivo high-throughput drug screening. Eur. J. Neurosci. 24(8), 2211-2222 (2006).
50. Daneman R, Barres BA: The blood-brain barrier - lessons from moody flies. Cell 123(1), 9-12 (2005).
51. Lionakis MS, Lewis RE, May GS et al.: Toll-deficient Drosophila flies as a fast, high-throughput model for the study of antifungal drug efficacy against invasive aspergillosis and Aspergillus virulence. J. Infect. Dis. 191(7), 1188-1195 (2005).
52. Desai UA, Pallos J, Ma AA et al.: Biologically active molecules that reduce polyglutamine aggregation and toxicity. Hum. Mol. Genet. 15(13), 2114-2124 (2006).
53. Agrawal N, Pallos J, Slepko N et al.: Identification of combinatorial drug regimens for treatment of Huntington's disease using Drosophila. Proc. Natl Acad. Sci. USA 102 (10), 3777-3781 (2005).